Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05949
Pages: 217
Jan 2020 | 1626 Views
 
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 90
Charts: 56
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Polycystic Ovarian Syndrome Treatment Market

Request Now !

Polycystic Ovarian Syndrome Treatment Market Outlook – 2026

The global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026. 

Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, various medications are used to regulate menstrual cycle and to manage symptoms of PCOS. 

Polycystic Ovarian Syndrome Treatment Market

Get more information on this report : Request Sample Pages

Increase in prevalence of PCOS, rise in awareness among patient population with increase in adoption of combination therapy drives the polycystic ovarian syndrome treatment market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medications, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the polycystic ovarian syndrome treatment market during the forecast period. However, lack of specific treatment for PCOS disorder is expected to restrain the growth of the market. The rise in prevalence of PCOS is expected to augment the demand for PCOS treatment medications. For instance, Centers for Disease Control and Prevention estimated that PCOS is one of the most common causes of female infertility, affecting 6 to 12% (as many as 5 million) of the American women of reproductive age. The number of PCOS patients is increasing due to the growing incidences of co-morbid conditions such as diabetes and obesity.

Polycystic Ovarian Syndrome Treatment Market Segmentation  

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).   

Segment Review 

By drug class, the market is categorized into insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. Presently, the insulin sensitizing agent segment is the major revenue contributing segment in 2018 and is estimated to show a significant market growth during the forecast period due to higher adoption of insulin sensitizing agents as the first line treatment for the management of PCOS.

Polycystic Ovarian Syndrome Treatment Market
By Drug Class

Your browser does not support the canvas element.

Oral Contraceptive is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

According to distribution channel, the polycystic ovarian syndrome treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict a significant growth during the forecast period, due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online providers, and rise in number of internet users.

Polycystic Ovarian Syndrome Treatment Market
By Distribution Channel

Your browser does not support the canvas element.

Drug Store and Retail Pharmacy holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the polycystic ovarian syndrome treatment market, owing to the growth in awareness about polycystic ovarian syndrome treatment, rise in adoption of polycystic ovarian syndrome treatment products will drive the market growth. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contributes to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are also expected to drive the growth of the polycystic ovarian syndrome treatment market in Asia-Pacific. 

Polycystic Ovarian Syndrome Treatment Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 5.4% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include Allergan plc., AstraZeneca plc., Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries. 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis along with the current polycystic ovarian syndrome treatment market trends and future estimations to elucidate the imminent investment pockets.
  • It offers polycystic ovarian syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize the prevailing opportunities in the market.
  • A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global polycystic ovarian syndrome treatment market growth.

Key Market Segments:

By Drug Class 

  • Insulin Sensitizing Agent
  • Oral Contraceptive
  • Antiandrogens
  • Anti-Obesity Drugs
  • Others

By Distribution Channel 

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. Key findings

2.2.1. Top investment pockets
2.2.2. Market player positioning, 2018

2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key forces shaping polycystic ovarian syndrome treatment industry/market

3.2.1. Moderate power of suppliers
3.2.2. High threat of new entrants
3.2.3. High threat of substitution
3.2.4. Moderate competitive rivalry
3.2.5. Moderate bargaining power of buyers

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. Increase in prevalence of PCOS
3.3.1.2. Increase in number of pipeline drugs
3.3.1.3. Surge in healthcare expenditure worldwide

3.3.2. Restraint

3.3.2.1. Lack of approved therapeutics for treatment of PCOS

3.3.3. Opportunities

3.3.3.1. Growth opportunities in emerging markets
3.3.3.2. Higher number of unmet needs for treatment of PCOS

3.3.4. Impact analysis

CHAPTER 4: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Insulin sensitizing agent

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Oral contraceptive

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Antiandrogens

4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Anti-obesity drugs

4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Others

4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY END USER

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospitals pharmacies

5.2.1. Market size and forecast
5.2.2. Market analysis, by country

5.3. Drug stores and retail pharmacies

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Online pharmacies

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

CHAPTER 6: POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. polycystic ovarian syndrome treatment market, by drug class
6.2.2.1.2. U.S. polycystic ovarian syndrome treatment market, by distribution channel

6.2.2.2. Canada

6.2.2.2.1. Canada polycystic ovarian syndrome treatment market, by drug class
6.2.2.2.2. Canada polycystic ovarian syndrome treatment market, by distribution channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico polycystic ovarian syndrome treatment market, by drug class
6.2.2.3.2. Mexico polycystic ovarian syndrome treatment market, by distribution channel

6.2.3. North America market size and forecast, by drug class
6.2.4. North America polycystic ovarian syndrome treatment market, by distribution channel

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany polycystic ovarian syndrome treatment market, by drug class
6.3.2.1.2. Germany polycystic ovarian syndrome treatment market, by distribution channel

6.3.2.2. France

6.3.2.2.1. France polycystic ovarian syndrome treatment market, by drug class
6.3.2.2.2. France polycystic ovarian syndrome treatment market, by distribution channel

6.3.2.3. UK

6.3.2.3.1. UK polycystic ovarian syndrome treatment market, by drug class
6.3.2.3.2. UK polycystic ovarian syndrome treatment market, by distribution channel

6.3.2.4. Italy

6.3.2.4.1. Italy polycystic ovarian syndrome treatment market, by drug class
6.3.2.4.2. Italy polycystic ovarian syndrome treatment market, by distribution channel

6.3.2.5. Spain

6.3.2.5.1. Spain polycystic ovarian syndrome treatment market, by drug class
6.3.2.5.2. Spain polycystic ovarian syndrome treatment market, by distribution channel

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe polycystic ovarian syndrome treatment market, by drug class
6.3.2.6.2. Rest of Europe polycystic ovarian syndrome treatment market, by distribution channel

6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe polycystic ovarian syndrome treatment market, by distribution channel

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan polycystic ovarian syndrome treatment market, by drug class
6.4.2.1.2. Japan polycystic ovarian syndrome treatment market, by distribution channel

6.4.2.2. China

6.4.2.2.1. China polycystic ovarian syndrome treatment market, by drug class
6.4.2.2.2. China polycystic ovarian syndrome treatment market, by distribution channel

6.4.2.3. Australia

6.4.2.3.1. Australia polycystic ovarian syndrome treatment market, by drug class
6.4.2.3.2. Australia polycystic ovarian syndrome treatment market, by distribution channel

6.4.2.4. India

6.4.2.4.1. India polycystic ovarian syndrome treatment market, by drug class
6.4.2.4.2. India polycystic ovarian syndrome treatment market, by distribution channel

6.4.2.5. South Korea

6.4.2.5.1. South Korea polycystic ovarian syndrome treatment market, by drug class
6.4.2.5.2. South Korea polycystic ovarian syndrome treatment market, by distribution channel

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific polycystic ovarian syndrome treatment market, by drug class
6.4.2.6.2. Rest of Asia-Pacific polycystic ovarian syndrome treatment market, by distribution channel

6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific polycystic ovarian syndrome treatment market, by distribution channel

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil polycystic ovarian syndrome treatment market, by drug class
6.5.2.1.2. Brazil polycystic ovarian syndrome treatment market, by distribution channel

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia polycystic ovarian syndrome treatment market, by drug class
6.5.2.2.2. Saudi Arabia polycystic ovarian syndrome treatment market, by distribution channel

6.5.2.3. South Africa

6.5.2.3.1. South Africa polycystic ovarian syndrome treatment market, by drug class
6.5.2.3.2. South Africa polycystic ovarian syndrome treatment market, by distribution channel

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA polycystic ovarian syndrome treatment market, by drug class
6.5.2.4.2. Rest of LAMEA polycystic ovarian syndrome treatment market, by distribution channel

6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA polycystic ovarian syndrome treatment market, by distribution channel

CHAPTER 7: COMPANY PROFILES

7.1. Allergan plc

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. AstraZeneca plc

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. Bayer AG.

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance

7.4. Bristol-Myers Squibb Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. Johnson and Johnson

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. Mylan N.V

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. Novartis AG

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. Pfizer Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. SANOFI

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. Teva Pharmaceutical Industries

7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Business performance
7.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 01. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 02. INSULIN SENSITIZING AGENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ORAL CONTRACEPTIVE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. ANTIANDROGENS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. ANTI-OBESITY DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 08. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 09. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 10. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 12. NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 13. U.S. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 14. U.S. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 15. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 16. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 17. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 18. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 19. NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 20. NORTH AMERICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 21. EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 22. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 23. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 24. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 25. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 26. UK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 27. UK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 28. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 29. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 30. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 31. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 32. REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 33. REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 34. EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 35. EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 36. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 38. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 39. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 40. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 41. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 42. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 43. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 44. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 45. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 46. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 47. REST OF ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 48. REST OF ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 49. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 50. ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 51. LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 53. BRAZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 54. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 55. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 56. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 57. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 58. REST OF LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 59. REST OF LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 60. LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 61. LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 62. ALLERGAN: COMPANY SNAPSHOT
TABLE 63. ALLERGAN: OPERATING SEGMENTS
TABLE 64. ALLERGAN: PRODUCT PORTFOLIO
TABLE 65. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 66. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 67. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 68. BAYER.: COMPANY SNAPSHOT
TABLE 69. BAYER.: OPERATING SEGMENTS
TABLE 70. BAYER.: PRODUCT PORTFOLIO
TABLE 71. BMS: COMPANY SNAPSHOT
TABLE 72. BMS: OPERATING SEGMENTS
TABLE 73. BMS: PRODUCT PORTFOLIO
TABLE 74. J&J: COMPANY SNAPSHOT
TABLE 75. J&J: OPERATING SEGMENTS
TABLE 76. J&J: PRODUCT PORTFOLIO
TABLE 77. MYLAN: COMPANY SNAPSHOT
TABLE 78. MYLAN: OPERATING SEGMENTS
TABLE 79. MYLAN: PRODUCT PORTFOLIO
TABLE 80. NOVARTIS: COMPANY SNAPSHOT
TABLE 81. NOVARTIS: OPERATING SEGMENTS
TABLE 82. NOVARTIS: PRODUCT PORTFOLIO
TABLE 83. PFIZER: COMPANY SNAPSHOT
TABLE 84. PFIZER: OPERATING SEGMENTS
TABLE 85. PFIZER: PRODUCT PORTFOLIO
TABLE 86. SANOFI: COMPANY SNAPSHOT
TABLE 87. SANOFI: OPERATING SEGMENTS
TABLE 88. SANOFI: PRODUCT PORTFOLIO
TABLE 89. TEVA: COMPANY SNAPSHOT
TABLE 90. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. TOP INVESTMENT POCKETS
FIGURE 02. MARKET PLAYER POSITIONING, 2018
FIGURE 03. GLOBAL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET SEGMENTATION
FIGURE 04. IMPACT ANALYSIS
FIGURE 05. COMPARATIVE ANALYSIS OF INSULIN SENSITIZING AGENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 06. COMPARATIVE ANALYSIS OF ORAL CONTRACEPTIVE MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 07. COMPARATIVE ANALYSIS OF ANTIANDROGENS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. U.S. POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 14. CANADA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 15. MEXICO POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 16. GERMANY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 17. FRANCE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 18. UK POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. ITALY POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. SPAIN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. REST OF EUROPE POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. JAPAN POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. CHINA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. AUSTRALIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. INDIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. SOUTH KOREA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. BRZIL POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. SAUDI ARABIA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. SOUTH AFRICA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. REST OF LAMEA POLYCYSTIC OVARIAN SYNDROME TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. ALLERGAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. ALLERGAN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 34. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 36. BAYER: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. BAYER.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. BAYER.: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. J&J: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 46. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 49. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 52. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. SANOFI: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES: REVENUE SHARE BY SEGMENTS 2018 ($MILLION)

 
 

Though there is no proper cure for PCOS but current polycystic ovarian syndrome treatment medications relieve patients from its symptoms and improves the quality of life. Different forms of drugs such as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others are used in management of PCOS. 

Increase in prevalence of PCOS, adoption of sedentary lifestyle, surge in level of stress and unhealthy diet, and rise in awareness regarding polycystic ovarian syndrome treatment significantly boosts the growth of the market. However, there is no approved drug for treatment of PCOS, which is anticipated to hinders the market growth.

North America is expected to remain dominant during the forecast period due to higher adoption of polycystic ovarian syndrome treatment products with increase in number target population. Early detection with higher health awareness among the general population drives the market growth in this region. In addition, Asia-Pacific is expected to offer lucrative opportunities for the key players during the forecast period, due to growing prevalence of PCOS along with rise in awareness of polycystic ovarian syndrome treatment products.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market value of global Polycystic Ovarian Syndrome Treatment market was $2,902.4 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global Polycystic Ovarian Syndrome Treatment market in 2019 is $3,040.8 million.

A. The adoption of Polycystic Ovarian Syndrome medication is expected to due to increase in prevalence of PCOS, rise in awareness among the patient population with increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancement for detection of PCOS influence the market growth. However, lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS may hamper the market growth

A. The base year calculated in the report is 2018.

A. Yes, Allergan is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.3%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 6.2%, 7.4%, 5.5%, 7.0%, 5.8%, respectively.

A. The North America market held a major share in the Polycystic Ovarian Syndrome Treatment market in 2018 and is expected to continue the trend in the forecasting period. This is attributed to higher prevalence of PCOS, higher healthcare awareness, presence of well-developed healthcare infrastructure along with early detection of the disease, presence of trained medical professionals, and easy accessibility to the therapeutics are majorly driving the market growth in North America

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Polycystic Ovarian Syndrome Treatment Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/m
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts